Back to search

University of Patras

Αντι-ιικά Τ-λεμφοκύτταρα με ανθεκτικότητα στα γλυκοκορτικοειδή μέσω CRISPR/Cas9 γονιδιακής επεξεργασίας, για τη θεραπεία ιογενών λοιμώξεων μετά από αλλογενή μεταμόσχευση

Abstract

dc:description

Viral and fungal infections are among the most fatal complications in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). While pharmacotherapy often fails or is associated with toxicity, adoptive immunotherapy (AI) with pathogen-specific T cells (pSTs) represents an attractive alternative. However, T cells perform suboptimally under immunosuppression, mainly steroids like Dexamethasone (Dex), which represent the first-line treatment of transplant-associated immunological complications, thus clinical implementation of AI is limited to patients not receiving high-dose steroids, a prerequisite for optimal T-cell function. The latter generates the obvious paradox of depriving the most susceptible to infections patients of the potential benefits of AI. To address this issue, in this study we aimed to i) evaluate the impact of Dexamethasone (Dex) on primary, activated, human T cells, ii) develop a CRISPR/Cas9 system to genetically disrupt the glucocorticoid receptor (GR) in lymphocytes, ultimately aiming to generate steroid-resistant pSTs and iii) develop a CRISPR/dCas9 system for epigenetic editing of the GR gene. Initially, proliferation, apoptosis and immunophenotype of human T cells were evaluated upon stimulation with CD3/CD80 and culture in the presence or absence of Dex. A 3-day exposure to Dex impaired the proliferation of CD3/CD80-pulsed primary T cells and induced early apoptosis over the “no Dex” condition. Immunophenotypically, Dex also increased T-regulatory cells (CD4+/CD25high) and upregulated the major T-cell exhaustion markers PD-1 and CTLA-4, over the “no Dex” condition. To inactivate the GR gene, we designed8 guide RNAs (sgRNAs) to target different genomic sequences corresponding to various domains of the GR (a transcription start site, and exons 2, 3, 4 and 5) and cloned them in plasmids with the Cas9 genes. Subsequently we generated lenti-viral vectors encoding the gRNAs and used them to transduce T2 lymphocytic cell line. After selection in culture supplemented with the appropriate antibiotic, transduced T2 cells were incubated in the presence or absence of Dex and their proliferation and GR disruption were evaluated. Cells transduced with a viral vector expressing Cas9 but no gRNA(empty vector) were used as negative control. Based on these results, the optimum sgRNA was selected for further use in T-cells. Subsequently, we generated a steroid-resistant T-cell product, simultaneously targeting 4 viruses [adenovirus, cytomegalovirus, Epstein Barr virus and BK virus] and the fungus Aspergillus fumigatus, by genetic disruption of the glucocorticoid receptor (GR) gene using CRISPR/Cas9 ribonucleoprotein delivery of the sgRNA selected previously. Following efficient on-target GR disruption and minimal off-target editing, the generated T cell product maintained the characteristics of pentavalent-STs, their unedited counterparts, including polyclonality, memory immunophenotype, specificity and cytotoxicity while they presented functional resistance to dexamethasone. Taking a step forward, we used a CRISPR/dCas9 system to epigenetically edit T2 cells with a sgRNApool and two different suppressors, DNMT3A methyltransferase and KRAB. T2 cells transduced with DNMT3A and sgRNA pool presented better proliferation rates ±Dex as contrasted to the empty-transduced cells, suggesting that pool contained sgRNAs which functionally disrupted GR. Overall, we confirm the inhibitory effect of Dex on primary T cells and provide an effective protocol to CRISPR/Cas9-disrupt the GR and confer resistance of T-cells to steroids. By this approach, we endeavor to ultimately offer the benefits of AI to the patients most vulnerable to infections, as those who receive high-dose steroids post allo-HSCT.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Alvanou, Maria
  • Αλβανού, Μαρία

Subjects

dc:subject × 15

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/54526

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Alvanou, Maria; Αλβανού, Μαρία. Αντι-ιικά Τ-λεμφοκύτταρα με ανθεκτικότητα στα γλυκοκορτικοειδή μέσω CRISPR/Cas9 γονιδιακής επεξεργασίας, για τη θεραπεία ιογενών λοιμώξεων μετά από αλλογενή μεταμόσχευση. University of Patras, 2023. http://hdl.handle.net/10442/hedi/54526